AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33954223 — intervention group
Group type: COMPARATOR
Intervention: Knotless suture-bridge repair
Number of subjects: 104
Study 33954265 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose dolutegravir
Number of subjects: 108
Study 33954265 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose dolutegravir
Number of subjects: 108
Study 33954265 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 108
Study 33954805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg)
Number of subjects: 114
Study 33954805 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg/kg)
Number of subjects: 114
Study 33954805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine or Propofol
Number of subjects: 114
Study 33954826 — intervention group
Group type: EXPERIMENTAL
Intervention: PARPi-FL (1000 nM)
Number of subjects: 12
Study 33954826 — intervention group
Group type: EXPERIMENTAL
Intervention: PARPi-FL (100 nM, 250 nM, 500 nM, 1000 nM)
Number of subjects: 12
Study 33954826 — intervention group
Group type: EXPERIMENTAL
Intervention: PARPi-FL
Number of subjects: 12
Study 33954826 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearing solution
Number of subjects: 12
Study 33954908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiographs
Number of subjects: 360
Study 33954908 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrasted radiographs
Number of subjects: 360
Study 33955129 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib treatment
Number of subjects: 652
Study 33955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing empowerment intervention (NEI)
Number of subjects: 172
Study 33955230 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no ECFC clones)
Number of subjects: 116
Study 33955230 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (clones with no replating capacity)
Number of subjects: 116
Study 33955230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (clones with replating capacity)
Number of subjects: 116
Study 33955240 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin 16.5% (cutaquig)
Number of subjects: 0
Study 33955376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-cytokine panel (Angiopoietin 2, hepatocyte growth factor, interleukin 8, resistin, soluble tumor necrosis factor receptor 1A)
Number of subjects: 193
Study 33955376 — intervention group
Group type: COMPARATOR
Intervention: Conventional laboratory tests and clinical scores
Number of subjects: 193
Study 33955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Molibresib (GSK525762)
Number of subjects: 193
Study 33955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Active metabolite composite (GSK3529246)
Number of subjects: 193
Study 33955700 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis
Number of subjects: 193
Study 33955778 — intervention group
Group type: EXPERIMENTAL
Intervention: Solyx SIS
Number of subjects: 281
Study 33955778 — intervention group
Group type: COMPARATOR
Intervention: Obtryx II TMUS
Number of subjects: 281
Study 33955798 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti-pertussis toxin (PT) antibodies measured using an enzyme-linked immunosorbent assay at 12 months (M12) and 24 months (M24) after enrollment.
Number of subjects: 104
Study 33955818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy intervention, details not available
Number of subjects: 0
Study 33955844 — intervention group
Group type: EXPERIMENTAL
Intervention: UV Guard sun protection system (UV dosimeter and smartphone app) with increasing intervention intensity over 3 periods.
Number of subjects: 42
Study 33956057 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor mobilization followed by apheresis
Number of subjects: 23
Study 33956083 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores categorized as 0, 1-10, 11-100, 101-400, >400 units
Number of subjects: 15915
Study 33956083 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores >400
Number of subjects: 15915
Study 33956083 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores >400 in patients treated with anthracyclines
Number of subjects: 15915
Study 33956083 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores >400 in patients who received a radiation boost
Number of subjects: 15915
Study 33956223 — intervention group
Group type: EXPERIMENTAL
Intervention: Social zeitgebers (affiliation with the labor market, contact with social network)
Number of subjects: 219
Study 33956223 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-activity pattern with early onset of the most active 10 hours
Number of subjects: 219
Study 33956223 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm with a large difference between periods of rest and activity
Number of subjects: 219
Study 33956223 — intervention group
Group type: EXPERIMENTAL
Intervention: Social zeitgebers, levels of physical activity, and circadian rhythm parameters
Number of subjects: 219
Study 33956223 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting regularity of daily routines
Number of subjects: 219
Study 33956283 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastography (TEG) with ADP Platelet Mapping assay kit
Number of subjects: 9
Study 33956283 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia and peripheral antalgic block
Number of subjects: 9
Study 33956283 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting for normalization of parameters
Number of subjects: 9
Study 33956283 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregometry-guided protocol
Number of subjects: 9
Study 33956283 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia
Number of subjects: 9
Study 33956667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer/BioNTech vaccine (1 dose)
Number of subjects: 124
Study 33956667 — intervention group
Group type: COMPARATOR
Intervention: Pfizer/BioNTech vaccine (2 doses)
Number of subjects: 124
Study 33956775 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise with enhanced therapeutic alliance (e.g., active listening, personalized conversation, empathy)
Number of subjects: 0
Study 33956775 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise with limited therapeutic alliance (e.g., one-way verbalization, brief interaction)
Number of subjects: 0
Study 33956845 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-fMRI and rt-fNIRS neural feedback sessions interleaved with motor learning sessions
Number of subjects: 4
Study 33956845 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-fMRI and rt-fNIRS neural feedback training
Number of subjects: 4
Study 33956845 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-fMRI and rt-fNIRS neural feedback
Number of subjects: 4
Study 33957168 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) over the right prefrontal cortex
Number of subjects: 111
Study 33957168 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 111
Study 33957168 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Signal task
Number of subjects: 111
Study 33957168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical activity diagnostic model
Number of subjects: 111
Study 33957227 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR eligibility at baseline
Number of subjects: 192
Study 33957227 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR eligibility after 2 years
Number of subjects: 192
Study 33957227 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR candidates at baseline
Number of subjects: 192
Study 33957227 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for ineligibility
Number of subjects: 192
Study 33957442 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan + oxaliplatin + 5-fluorouracil + leucovorin (NALIRIFOX)
Number of subjects: 0
Study 33957650 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual rotation
Number of subjects: 236
Study 33957650 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 236
Study 33957864 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid fluid (5-20 mL/kg) administered intravenously or by mouth to volunteers
Number of subjects: 63
Study 33957864 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid fluid (5-20 mL/kg) administered intravenously or by mouth to surgical patients
Number of subjects: 63
Study 33957864 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive Hb measurement in volunteers
Number of subjects: 63
Study 33957864 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive Hb measurement in surgical patients
Number of subjects: 63
Study 33957901 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg daily with copper gluconate (8 mg of elemental copper)
Number of subjects: 21
Study 33957901 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg daily with copper gluconate (2, 4, 6 mg of elemental copper)
Number of subjects: 21
Study 33957901 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 33957997 — intervention group
Group type: EXPERIMENTAL
Intervention: iSTEP
Number of subjects: 66
Study 33957997 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-m ISWT
Number of subjects: 66
Study 33957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment/retention rates
Number of subjects: 66
Study 33957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol completion
Number of subjects: 66
Study 33957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events/reactions (SAE/SARs)
Number of subjects: 66
Study 33958126 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 40
Study 33958126 — intervention group
Group type: EXPERIMENTAL
Intervention: mid-regional pro-atrial natriuretic peptide (MR-proANP)
Number of subjects: 40
Study 33958126 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 40
Study 33958170 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-annular TAVR in de novo stenosis
Number of subjects: 47420
Study 33958170 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-annular TAVR in TAV-in-SAV
Number of subjects: 47420
Study 33958170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe PPM
Number of subjects: 47420
Study 33958170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedural factors for severe PPM
Number of subjects: 47420
Study 33958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely reperfusion with primary percutaneous coronary intervention (PCI) within 90 min for patients with S2C<60 min
Number of subjects: 20005
Study 33958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely reperfusion with PCI within 90 min for patients with 1 hour<S2C≤2 hours
Number of subjects: 20005
Study 33958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely reperfusion with PCI within 90 min for patients with 2 hours<S2C≤6 hours
Number of subjects: 20005
Study 33958491 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely reperfusion with PCI within 90 min for patients with 6 hours<S2C≤24 hours
Number of subjects: 20005
Study 33959007 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib maintenance treatment, dosage and duration not specified
Number of subjects: 0
Study 33959007 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33959044 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (CBT) for depression
Number of subjects: 0
Study 33959044 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33959132 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline plasmatic level of BTN2A1 (sBTN2A1high)
Number of subjects: 38
Study 33959132 — intervention group
Group type: COMPARATOR
Intervention: Low baseline plasmatic level of BTN2A1 (sBTN2A1low)
Number of subjects: 38
Study 33959132 — intervention group
Group type: EXPERIMENTAL
Intervention: sBTN2A1high
Number of subjects: 38
Study 33959195 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (EC-TH)
Number of subjects: 140
Study 33959195 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/carboplatin/trastuzumab (TCH)
Number of subjects: 140
Study 33959198 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 33959198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33959627 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital handover checklists
Number of subjects: 0
Study 33959627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no digital handover checklists)
Number of subjects: 0
Study 33959689 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-quality diet (measured by Healthy Eating Index-2010 scores)
Number of subjects: 540
Study 33959689 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-quality diet
Number of subjects: 540
Study 33959805 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-RAR technique
Number of subjects: 105
Study 33959925 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Shock (IV procainamide followed by electrical cardioversion)
Number of subjects: 76
Study 33959925 — intervention group
Group type: COMPARATOR
Intervention: Shock-Only (placebo infusion followed by electrical cardioversion)
Number of subjects: 76
Study 33959925 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Shock
Number of subjects: 76
Study 33959925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 33960144 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-TM (+) group
Number of subjects: 5625
Study 33960144 — intervention group
Group type: COMPARATOR
Intervention: AF-TM (-) group
Number of subjects: 5625
Study 33960144 — intervention group
Group type: COMPARATOR
Intervention: SR group
Number of subjects: 5625
Study 33960144 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 5625
Study 33960681 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin monotherapy (T)
Number of subjects: 2213
Study 33960681 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (T+PLD)
Number of subjects: 2213
Study 33960681 — intervention group
Group type: EXPERIMENTAL
Intervention: History of prior cardiac medication
Number of subjects: 2213
Study 33960693 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth tool for child growth monitoring and nutritional status assessment
Number of subjects: 3529
Study 33960693 — intervention group
Group type: COMPARATOR
Intervention: Standard paper-based WHO growth charts
Number of subjects: 3529
Study 33960826 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized algorithm for genetic variant interpretation based on 2015 ACMG/AMP guidelines
Number of subjects: 131
Study 33960826 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance
Number of subjects: 131
Study 33960843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered Escalating Real-Time Adherence (TERA) intervention
Number of subjects: 87
Study 33960843 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 87
Study 33960949 — intervention group
Group type: EXPERIMENTAL
Intervention: haMSter mobile health solution for remote monitoring of patient-reported outcomes (PROs)
Number of subjects: 50
Study 33961019 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab + idelalisib (induction phase for 6 cycles)
Number of subjects: 48
Study 33961019 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib alone (maintenance phase for ≤2 years)
Number of subjects: 48
Study 33961111 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pathological high myopia (HM) group
Number of subjects: 35
Study 33961111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 33961287 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP-4199 (85:15 ratio of aramisulpride to esamisulpride)
Number of subjects: 0
Study 33961287 — intervention group
Group type: EXPERIMENTAL
Intervention: aramisulpride
Number of subjects: 0
Study 33961287 — intervention group
Group type: EXPERIMENTAL
Intervention: esamisulpride
Number of subjects: 0
Study 33961291 — intervention group
Group type: EXPERIMENTAL
Intervention: Least restrictive suicide risk exclusion criteria (more than 0 on the Personal Health Questionnaire)
Number of subjects: 0
Study 33961291 — intervention group
Group type: COMPARATOR
Intervention: More restrictive suicide risk exclusion criteria (more than 1 on the Personal Health Questionnaire)
Number of subjects: 0
Study 33961331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study 33961331 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4047
Study 33961488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg once daily
Number of subjects: 34
Study 33961501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) and long-term exercise training
Number of subjects: 0
Study 33961795 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 78
Study 33962115 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises (VRE)
Number of subjects: 40
Study 33962115 — intervention group
Group type: COMPARATOR
Intervention: Short Foot Exercises (SFE)
Number of subjects: 40
Study 33962483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation (CR)
Number of subjects: 580
Study 33962483 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise training)
Number of subjects: 580
Study 33962566 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonertinib for 2 months followed by concurrent radiotherapy (induction group, arm A)
Number of subjects: 0
Study 33962566 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent almonertinib with thoracic radiotherapy (concurrent group, arm B)
Number of subjects: 0
Study 33962566 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonertinib (induction group)
Number of subjects: 0
Study 33962603 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network (RNN) model
Number of subjects: 12596
Study 33962603 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent Neural Network (RNN) model with inclusion of function of other organs
Number of subjects: 12596
Study 33962603 — intervention group
Group type: COMPARATOR
Intervention: Random Forest (RF) and Logistic Regression (LR) models
Number of subjects: 12596
Study 33963002 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sequencing intervention, details not available
Number of subjects: 0
Study 33963002 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hit intervention, details not available
Number of subjects: 0
Study 33963014 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT (40 Gy in 5 fractions or 24 Gy in 3 fractions) with nivolumab
Number of subjects: 21
Study 33963084 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management device for adherence to hydroxychloroquine
Number of subjects: 26
Study 33963573 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily for seven consecutive days
Number of subjects: 21
Study 33963686 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily for 24 months
Number of subjects: 0
Study 33963686 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (dose-dependent)
Number of subjects: 0
Study 33963686 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (dose-response model)
Number of subjects: 0
Study 33963740 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG ≥5.1 mmol/L
Number of subjects: 1035
Study 33963740 — intervention group
Group type: EXPERIMENTAL
Intervention: 2hPG ≥8.5 mmol/L
Number of subjects: 1035
Study 33963740 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG
Number of subjects: 1035
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate transfers
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of disability
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to receive prompt medical advice
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: Existence of an Alzheimer's disease special care unit in the NH
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: NH staff trained on advance directives
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling the SAMU (mobile emergency medical unit)
Number of subjects: 1037
Study 33964225 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization costs prior to transfer
Number of subjects: 1037
Study 33964451 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS)
Number of subjects: 0
Study 33964512 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (ECS) with 15 to 20 mm Hg and 20 to 36 mm Hg pressure
Number of subjects: 57
Study 33964512 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive elastic compression stockings (ECS)
Number of subjects: 57
Study 33964512 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (ECS)
Number of subjects: 57
Study 33964512 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 33964664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use (1004 participants)
Number of subjects: 2500
Study 33964664 — intervention group
Group type: COMPARATOR
Intervention: No aspirin use (1494 participants)
Number of subjects: 2500
Study 33964856 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure children
Number of subjects: 9147
Study 33964856 — intervention group
Group type: COMPARATOR
Intervention: Food-secure children
Number of subjects: 9147